Clinical trial
NY-ESO-1 Protein With Montanide and CpG 7909 as Cancer Vaccine in Several Tumors
NCT00299728 · Ludwig Institute for Cancer Research, Other · Completed
Key facts
| NCT number | NCT00299728 |
|---|---|
| Title | NY-ESO-1 Protein With Montanide and CpG 7909 as Cancer Vaccine in Several Tumors |
| Official title | A Phase I Study Using Vaccination With NY-ESO-1 Recombinant Protein Mixed With CpG 7909 and Montanide ISA-51 VG in Patients With Cancers That Often Express NY-ESO-1. |
| Lead sponsor | Ludwig Institute for Cancer Research, Other |
| Collaborators | NYU Langone Health |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Tumors |
| Intervention type | Biological |
| Interventions | NY-ESO-1 Protein Vaccine |
| Enrollment | 22 |
| Start date | Mar 21, 2006 |
| Primary completion | Oct 10, 2006 |
| Completion | Jan 10, 2014 |
| First posted | Mar 7, 2006 |
| Last update posted | Oct 10, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: